OrthoPediatrics Post-Earnings: What the Print Changed and What It Didn't

OrthoPediatrics Corp. has just passed through its Q3 earnings release, and the question now is whether Tuesday's print reshapes the story that dominated the pre-earnings notes, or whether the same tensions remain in place.

The earnings data in the snapshot is thin on post-release price reaction, but the stock closed at $23.82 on October 27, down 0.8% on the day and modestly below the $24.50 level cited in the pre-earnings note from October 25. That gives the print a slightly negative initial read, though the stock is still up 1.4% on the week and 5.6% on the month. The next scheduled event is November 6, nine days out, which the earnings schedule now lists as the follow-on date, likely a conference or analyst call rather than another quarterly release. Whatever the market's immediate verdict on the Q3 numbers, the stock has not broken down from its recent range.

The positioning picture is largely unchanged from the pre-earnings notes. Short interest has crept higher this week, rising 6.5% to reach 3.8% of the free float, continuing a trend that began in late September when shares short were closer to 825,000. That is still a modest absolute level, and the borrow market remains very loose. Availability is running at over 1,300%, meaning there are more than thirteen times as many shares available to borrow as are currently lent out, well above even the 52-week tightest reading of around 393%. Borrowing costs have dropped sharply from the 2% range seen earlier in October to around 0.44%, the lowest in over a month. The options market has settled: the put/call ratio is 0.44, roughly 1.5 standard deviations above the 20-day average, still slightly elevated but no longer accelerating. Collectively, this looks like positioning that is cautious rather than aggressive in either direction.

The Street remains constructive, though not uniformly so. Four analysts carry Buy or equivalent ratings, with a mean price target of $30.25 against a current price of $23.82, implying around 27% upside. The most recent analyst move was BTIG's September reiteration of its Buy and $29 target, unchanged from August when it raised from $24. Needham is the most bullish at $35, raised from $30 after the August print. Truist sits on the other side at Hold, with a $20 target raised from $17 in July, still below the current stock price. The bull case centres on the "Super Cycle" of post-EU MDR product launches across Trauma, Scoliosis, and Specialty Bracing, with FY26 revenue guidance of roughly $263 million to $267 million implying continued double-digit growth. Bears point to execution risk, distributor productivity, and the limited pricing power that comes from competing against far larger orthopedic platforms. The forward EPS improvement factor scores at the 86th percentile, one of the stronger readings in the snapshot, while near-term EPS momentum sits in the 11th percentile, a gap that reflects the company's continued unprofitability even as its revenue trajectory improves. The EV/EBITDA multiple is near 19.4x, down modestly over the past month.

The ownership story is the most structurally interesting element and has not changed materially since the pre-earnings notes documented it. David R. Pelizzon, who files as a Schedule 13D activist holder, reduced his stake from 25.2% to 23.9% as of September 11, the most recent 13D/A amendment. Squadron Capital, the institutional vehicle aligned with Pelizzon and Jennifer Pritzker, reported selling 700,000 shares as of September 10, leaving the position at 6.2 million shares, still around 23.75% of outstanding shares. The combined net insider position across the past 90 days is negative 2.1 million shares, with proceeds near $47 million. None of the trades carried 10b5-1 designations. These are the controlling-shareholder-director cluster reducing exposure at prices between $21 and $23, a level the stock is now trading at again after briefly touching higher ground. The Schedule 13D/G disclosure caveat applies: stakes are as last reported and holders dropping below 5% need not file again, so the picture could have shifted further without public notice.

With the print now behind it and the November 6 event nine days away, the next focus is whether the Q3 revenue number confirms the 13.3% year-over-year growth rate seen in Q1, and whether management's commentary on distributor momentum and the product launch pipeline either validates or tempers the gap between Needham's $35 target and Truist's $20 Hold.